Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
The Cancer Clinic, St. Olav's University Hospital, Trondheim, Norway.
Br J Haematol. 2020 Nov;191(3):418-425. doi: 10.1111/bjh.16674. Epub 2020 May 5.
Population-based studies from high-quality nationwide cancer registries provide an important alternative to clinical trials in the assessment of the impact of modern myeloma treatment. Based on data from the Cancer Registry of Norway, we investigated trends in incidence and relative survival (RS) for 10 524 patients in three age groups diagnosed between 1982 and 2017. Nationwide myeloma drug consumption statistics were obtained from the Norwegian Institute of Public Health. Patients aged <65 years had a steady increase in both 5- and 10-year RS across all calendar periods from 1982. For patients aged 65-79 years, RS was stable until the calendar period 1998-2002, followed by an improvement in both 5- and 10-year RS. The 5-year RS for patients aged ≥80 years also increased significantly between the first and the last calendar period. In conclusion, we demonstrate a significant improvement in 5-year RS in all age groups. Improved RS in patients aged ≥80 years at the time of diagnosis is only rarely described in other population-based studies. For patients aged ≥65 years, the improvement in RS coincides with the introduction of modern drugs, whereas patients aged <65 years had an ongoing improvement before the introduction of autologous stem-cell transplant.
基于高质量全国癌症登记处的人群研究为评估现代骨髓瘤治疗的影响提供了临床试验的重要替代方法。根据来自挪威癌症登记处的数据，我们调查了 1982 年至 2017 年间三个年龄组的 10524 名患者的发病率和相对生存率 (RS) 趋势。我们从挪威公共卫生研究所获得了全国骨髓瘤药物消费统计数据。<65 岁的患者在所有时期的 5 年和 10 年 RS 都呈稳步上升趋势。对于 65-79 岁的患者，RS 在 1998-2002 日历期间之前保持稳定，随后 5 年和 10 年 RS 均有所改善。≥80 岁患者的 5 年 RS 也在两个第一个和最后一个日历期间之间显著增加。总之，我们证明了所有年龄组的 5 年 RS 均有显著提高。在其他基于人群的研究中，很少有描述≥80 岁诊断时 RS 改善的情况。对于≥65 岁的患者，RS 的改善与现代药物的引入相吻合，而<65 岁的患者在自体干细胞移植引入之前就一直在改善。
